Press releases

YEAR: ALL
  • All

2024


May 23, 2024 IRLAB strengthens its liquidity by drawing SEK 25 million on a previously secured loan facility

May 22, 2024 / REGULATORY Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB

May 22, 2024 IRLAB has administered the first dose in a Phase I clinical trial with the drug candidate IRL757

May 22, 2024 IRLAB broadcasts the annual general meeting live

May 21, 2024 IRLAB presents at ABGSC Investor Days

May 8, 2024 / REGULATORY IRLAB publishes interim report for the period January-March 2024

May 7, 2024 / REGULATORY IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy

May 6, 2024 IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757

May 6, 2024 IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast

April 29, 2024 / REGULATORY IRLAB publishes Annual Report for 2023

April 16, 2024 IRLAB to present at Redeye Investor Forum

March 22, 2024 IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam

March 19, 2024 IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis

February 29, 2024 IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG

February 28, 2024 IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7

February 27, 2024 IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases

February 22, 2024 / REGULATORY IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam

February 7, 2024 / REGULATORY IRLAB publishes year-end report for the period January-December 2023

February 6, 2024 IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines

January 31, 2024 IRLAB: Invitation to the Year-end Report 2023 presentation and webcast

January 3, 2024 IRLAB is granted an end-of-Phase 2 meeting with the FDA for the Phase III-ready mesdopetam program

2023


December 27, 2023 / REGULATORY IRLAB extends CEO appointment

December 22, 2023 / REGULATORY IRLAB increases its liquidity with a loan facility of up to SEK 55 million that extends financial runway and increases business opportunities

December 21, 2023 / REGULATORY IRLAB receives grant from The Michael J. Fox Foundation to support development of IRL757 for the treatment of apathy

December 21, 2023 IRLAB’s drug candidate IRL757 is Phase I ready

December 18, 2023 IRLAB submits request for an end-of-Phase 2 meeting with the FDA for the Phase III-ready mesdopetam program

December 12, 2023 IRLAB is granted additional patent for drug candidate pirepemat that expands its patent protection

November 21, 2023 IRLAB to present at SEB Annual Healthcare Seminar on November 23, 2023

November 20, 2023 IRLAB to present at Redeye Life Science Day on November 23, 2023

November 20, 2023 IRLAB to present at ABGSC Investor Days on November 22, 2023

November 7, 2023 / REGULATORY Nomination committee appointed for IRLAB’s annual general meeting 2024

October 25, 2023 / REGULATORY IRLAB publishes interim report for the period January-September 2023

October 24, 2023 IRLAB to present at BioStock Life Science Fall Summit on October 26, 2023

October 19, 2023 IRLAB: Invitation to the interim report for Q3 2023 presentation and webcast

October 11, 2023 IRLAB shares invitation to Capital Markets Day on October 17, 2023

October 10, 2023 IRLAB to present at Redeye Neurology Theme Event on October 11, 2023

October 10, 2023 IRLAB signs Phase III regulatory US consultants to support preparation for mesdopetam’s end-of-Phase 2 meeting with the US FDA

September 13, 2023 IRLAB to present at Pareto Securities’ Healthcare Conference in Stockholm on September 14, 2023

September 11, 2023 Save the date: IRLAB holds Capital Markets Day on October 17, 2023

August 30, 2023 / REGULATORY IRLAB publishes interim report for the period January-June 2023

August 23, 2023 IRLAB: Invitation to the interim report for Q2 2023 presentation and webcast

August 21, 2023 IRLAB provides update on mesdopetam’s Phase IIb study data and the plans toward Phase III

August 21, 2023 / REGULATORY IRLAB secures full ownership of the mesdopetam project and continues product development

July 17, 2023 IRLAB’s Phase IIb study with pirepemat passes DSMB safety review with unanimous recommendation to continue the ongoing Phase IIb study

June 20, 2023 / REGULATORY Report from the Annual General meeting of IRLAB Therapeutics AB

June 20, 2023 IRLAB to present data from the Phase IIb study of mesdopetam in PD-LIDs at the MDS Congress 2023

June 13, 2023 IRLAB to present at the scientific conference XIV Triennial Meeting of the International Basal Ganglia Society (IBAGS)

June 1, 2023 IRLAB to present at Redeye Growth Day 2023 in Stockholm on June 1, 2023

May 31, 2023 IRLAB has activated all 38 study sites in the Phase IIb study of pirepemat aiming to improve balance and reduce falls in Parkinson’s disease

May 30, 2023 IRLAB to present at ABGSC’s Life Science Summit in Stockholm on May 31, 2023

May 16, 2023 / REGULATORY IRLAB Therapeutics and the McQuade Center for Strategic Research and Development Enter into Agreement to Evaluate IRLAB’s Neuropsychiatric Programs IRL757 and IRL942

May 10, 2023 / REGULATORY IRLAB publishes interim report for the period January-March 2023

May 3, 2023 / REGULATORY IRLAB comments on statements in Ipsen’s 2022 Universal Registration Document and the further development of mesdopetam

May 3, 2023 IRLAB: Invitation to the interim report for Q1 2023 presentation and webcast

April 28, 2023 / REGULATORY IRLAB publishes the Annual Report for 2022

April 20, 2023 / REGULATORY IRLAB announces new date for publication of the annual report

March 22, 2023 IRLAB: Invitation to symposium on Parkinson’s disease and its management dilemma at the AD/PD™ 2023 on March 31, 2023

March 17, 2023 IRLAB to hold four presentations at scientific congress AD/PD™ 2023

March 6, 2023 IRLAB to present at ABGSC Investor Day in Stockholm on March 8, 2023

February 23, 2023 / REGULATORY IRLAB publishes Year-end report for the period January-December 2022

February 21, 2023 / REGULATORY IRLAB reports that board member leaves the company’s Board

February 20, 2023 / REGULATORY IRLAB changes CEO and appoints new Chairman

February 16, 2023 IRLAB: Invitation to the year-end report 2022 presentation and webcast

February 13, 2023 IRLAB updates on portfolio development milestones

January 17, 2023 / REGULATORY IRLAB announces top-line results from Phase IIb trial of mesdopetam (IRL790) in Parkinson’s disease

January 12, 2023 IRLAB nominates IRL1117 as drug candidate from the P003 project to develop a novel treatment for Parkinson’s disease

January 6, 2023 IRLAB to present at the 6th Neuroscience Innovation Forum in San Francisco on January 8, 2023

2022


December 21, 2022 IRLAB has been informed that the Swedish ECA investigation is closed

December 15, 2022 IRLAB to present at DNB Nordic Healthcare Conference in Oslo

December 14, 2022 IRLAB reports Last Patient Last Visit (“LPLV”) achieved in Phase IIb clinical study of mesdopetam in PD-LIDs with top-line results anticipated mid-January 2023

November 24, 2022 IRLAB to present at Redeye Life Science Day 2022

November 23, 2022 IRLAB to participate in the SEB Annual Healthcare Summit on November 23, 2022

November 15, 2022 IRLAB highlights new preclinical data indicating Phase IIb drug candidate mesdopetam’s powerful efficacy in Parkinson’s psychosis and PD-LIDs

November 15, 2022 / REGULATORY Nomination committee in IRLAB appointed ahead of annual general meeting 2023

November 14, 2022 IRLAB to participate at LSX Inv€$tival Showcase in London, UK

November 9, 2022 / REGULATORY IRLAB publishes interim report for the period January–September 2022

November 2, 2022 IRLAB: Invitation to the third quarter results presentation and webcast

October 11, 2022 IRLAB to present the company at Redeye Neurology Seminar on October 12, 2022

September 28, 2022 IRLAB to present the company at ProHearings on September 29, 2022

September 13, 2022 IRLAB to present at ABGSC Investor Day on September 13, 2022

September 12, 2022 IRLAB completes recruitment in Phase IIb study of mesdopetam (IRL790) in patients with Parkinson’s levodopa-induced dyskinesias

September 7, 2022 IRLAB to present at Pareto Securities’ 13th Annual Healthcare Conference

September 6, 2022 IRLAB’s partner Ipsen initiates clinical studies in line with mesdopetam’s development plan

August 31, 2022 IRLAB assists Swedish Economic Crime Authority

August 24, 2022 / REGULATORY IRLAB publishes interim report for the period January–June 2022

August 15, 2022 IRLAB: Invitation to the second quarter and half-year 2022 results presentation and webcast

August 1, 2022 / REGULATORY Changed number of shares and votes in IRLAB Therapeutics AB

July 11, 2022 / REGULATORY IRLAB expands Phase IIb/III PD-LIDs study with mesdopetam to support Phase III program and expects completion of enrollment during the summer

June 9, 2022 / REGULATORY IRLAB strengthens its management team by appointing Richard Godfrey as new CEO and Nicholas Waters as Executive Vice President and Head of R&D

May 11, 2022 / REGULATORY Report from the Annual General Meeting of IRLAB Therapeutics AB

May 11, 2022 / REGULATORY IRLAB interim report January – March, 2022

May 4, 2022 IRLAB announces invitation to presentation of the interim report for Q1 2022

April 22, 2022 / REGULATORY IRLAB acquires know-how connected to the P003 project aimed at an innovative treatment for Parkinson’s disease

April 11, 2022 / REGULATORY NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF 2022

April 8, 2022 / REGULATORY IRLAB publishes the Annual Report for 2021

March 21, 2022 IRLAB nominates new candidate drug, IRL757, to treat apathy in neurological disorders

March 18, 2022 Welcome to IRLAB’s Capital Markets Day 2022

February 23, 2022 Invitation to IRLAB’s Capital Markets Day 2022– Insights into our growth strategy

February 23, 2022 / REGULATORY IRLAB’s year-end report January 1 – December 31, 2021

February 16, 2022 Invitation to the presentation of IRLAB´s year-end report January – December 2021

2021


December 31, 2021 / REGULATORY Board member leaves IRLAB for another assignment

December 21, 2021 / REGULATORY IRLAB obtains regulatory approval to conduct Phase IIb study with pirepemat – one step closer to improving balance and reducing fall injuries for people living with Parkinson’s disease

November 10, 2021 / REGULATORY IRLAB publishes interim report for July 1 – September 30, 2021

November 5, 2021 / REGULATORY Nomination committee in IRLAB appointed ahead of annual general meeting 2022

November 5, 2021 Invitation to the presentation of IRLAB´s Interim report January – September 2021

September 2, 2021 IRLAB obtains strengthened patent protection for Phase II candidate pirepemat

August 25, 2021 / REGULATORY IRLAB publishes interim report for April 1 – June 30, 2021

July 16, 2021 IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam

July 15, 2021 / REGULATORY Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease

June 15, 2021 IRLAB’s drug candidate pirepemat’s Phase I data published in scientific journal CPDD

June 2, 2021 IRLAB announces that equity research company Edison initiates coverage of the company

May 25, 2021 IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P

May 6, 2021 / REGULATORY Report from the annual general meeting of IRLAB Therapeutics AB

May 6, 2021 / REGULATORY IRLAB interim report January – March 2021

May 5, 2021 IRLAB publishes recorded speech and company presentation prior to digital AGM

April 15, 2021 / REGULATORY IRLAB’s annual report for 2020 is now available on the company’s website

April 8, 2021 / REGULATORY IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal

March 25, 2021 IRLAB’s drug candidate mesdopetam’s mechanism of action receives confirmation by independent scientists

March 9, 2021 First European patients dosed in IRLAB’s Phase IIb/III mesdopetam study

February 24, 2021 / REGULATORY IRLAB’s Year-end report January 1 – December 31, 2020

January 29, 2021 / REGULATORY IRLAB announces change in share capital and number of shares following registered directed share issue

January 12, 2021 IRLAB presents application of deep learning on multidimensional CNS drug efficacy data

January 11, 2021 IRLAB presents new data indicating that mesdopetam could prevent dyskinesia in Parkinson’s Disease

2020


December 18, 2020 / REGULATORY IRLAB Therapeutics carries out a directed share issue in the amount of SEK 130,000,000

December 8, 2020 IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam

November 4, 2020 IRLAB starts Phase IIb/III study with mesdopetam in the US

October 30, 2020 / REGULATORY Nomination committee in IRLAB appointed ahead of annual general meeting 2021

October 1, 2020 / REGULATORY IRLAB’s mesdopetam IND accepted by the US FDA

September 30, 2020 / REGULATORY IRLAB’s shares are now traded on Nasdaq Stockholm Main Market

September 25, 2020 / REGULATORY IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market

September 23, 2020 / REGULATORY IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market

September 10, 2020 IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET

August 3, 2020 IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO

July 9, 2020 IRLAB’s clinical drug candidate IRL752 published in JPET

June 24, 2020 IRLAB’s mesdopetam featured on cover of top-tier publication JPET

June 4, 2020 IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON

May 7, 2020 / REGULATORY Report from the Annual General Meeting of IRLAB Therapeutics AB

May 6, 2020 IRLAB’s clinical drug candidate mesdopetam published in JPET

April 7, 2020 / REGULATORY IRLAB publishes the annual report for 2019

March 23, 2020 IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders

February 27, 2020 / REGULATORY IRLAB’s rights issue oversubscribed

February 7, 2020 / REGULATORY IRLAB publishes prospectus relating to the rights issue

February 6, 2020 / REGULATORY IRLAB launches new website

February 4, 2020 IRLAB’s IRL790 receives new name ‘mesdopetam’

2019


December 12, 2019 / REGULATORY IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million

December 12, 2019 / REGULATORY IRLAB intends to make a capital raise of approximately SEK 215 million

November 6, 2019 IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe

October 21, 2019 IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference

October 17, 2019 / REGULATORY Nomination committee in IRLAB appointed

September 26, 2019 / REGULATORY IRLAB’s IRL790 is proposed a unique INN by WHO

September 23, 2019 IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders

August 28, 2019 IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results

July 16, 2019 IRLAB reports top line results from Phase IIa study with IRL790

May 28, 2019 IRLAB and research consortium awarded MSEK 2.9 Vinnova grant

May 27, 2019 / REGULATORY Today, May 27, is the last day of trading in IRLAB’s share before share split

May 17, 2019 / REGULATORY IRLAB announces share split

May 9, 2019 IRLAB completes recruitment for its Phase II study with IRL790 in Parkinson’s disease patients with dyskinesia

April 25, 2019 / REGULATORY IRLAB – Resolutions at Annual General Meeting 2019

April 3, 2019 / REGULATORY IRLAB Therapeutics AB publishes annual report for 2018

March 14, 2019 IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review

2018


2017